Methylphenidate
Prescription ·Exploratory record · not publication-reviewed ·Updated July 13, 2026
Prescription central nervous system stimulant (Schedule II controlled substance) approved for attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. One of the most extensively studied medications for ADHD with decades of evidence supporting efficacy. Available in multiple formulations offering various durations of action. Carries risk of abuse, cardiovascular effects, and growth suppression in children. Dosage must be determined by your prescribing physician.
Exploratory record, not a reviewed medical publication.
See the editorial and medical-review policies for the publication gate.
This generated database record has not completed a claim-level review by a qualified human medical reviewer. Bibliography links and evidence labels are not approval. The page remains available for reference and is excluded from search indexing.
What the research says.
A quick, data-only summary. The full evidence, dosing, and sources are below.
Prescription central nervous system stimulant (Schedule II controlled substance) approved for attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. NutriStack rates the supporting evidence as strong. Common adult dosing is 5–60 mg daily for IR; 18–72 mg daily for Concerta ER (as prescribed by your physician), though a prescriber sets the actual dose. This profile indexes 11 sources.
The bottom line
Evidence rating strong. Most-documented uses: improved attention and focus, reduced hyperactivity, decreased impulsivity. 11 sources indexed (2009–2026), with 0 interaction records on file.
How it works, mechanistically.
Core mechanism
Blocks the reuptake of dopamine and norepinephrine by inhibiting their respective transporters (DAT and NET) in the prefrontal cortex and striatum. Unlike amphetamines, methylphenidate primarily acts as a reuptake inhibitor rather than a releaser of catecholamines, resulting in increased synaptic dopamine and norepinephrine concentrations.
Dosing & protocol.
Can be taken with or without food. Concerta tablets should be swallowed whole. Ritalin LA capsules may be opened and sprinkled on applesauce. Take in the morning to avoid insomnia.
Full safety detail.
Side effects
- Decreased appetite
- Insomnia
- Headache
- Abdominal pain
- Tachycardia and increased blood pressure
- Nervousness and anxiety
- Weight loss
- Irritability
Sources, by evidence tier.
Numbered references. Citations throughout the page link here.
Meta-analyses & systematic reviews
7- 1Methylphenidate-Type Psychostimulants for Cancer-Related Fatigue: Updated Meta-Analysis of Randomized Controlled TrialsPMIDCosta BA, Sheppard R, Coelho HGB et al. · Journal of the National Comprehensive Cancer Network : JNCCN · 2026
Costa BA, Sheppard R, Coelho HGB et al.. Methylphenidate-Type Psychostimulants for Cancer-Related Fatigue: Updated Meta-Analysis of Randomized Controlled Trials. Journal of the National Comprehensive Cancer Network : JNCCN. 2026
- 2Methylphenidate and Atomoxetine in Pregnancy and Possible Adverse Fetal Outcomes: A Systematic Review and Meta-AnalysisPMIDdi Giacomo E, Confalonieri V, Tofani F et al. · JAMA network open · 2024
di Giacomo E, Confalonieri V, Tofani F et al.. Methylphenidate and Atomoxetine in Pregnancy and Possible Adverse Fetal Outcomes: A Systematic Review and Meta-Analysis. JAMA network open. 2024
- 3Effect of methylphenidate on height in pediatric attention-deficit hyperactivity disorder patients: a systematic review and meta-analysisPMIDDuong KL, Yang BR, Yun HY et al. · European child & adolescent psychiatry · 2024
Duong KL, Yang BR, Yun HY et al.. Effect of methylphenidate on height in pediatric attention-deficit hyperactivity disorder patients: a systematic review and meta-analysis. European child & adolescent psychiatry. 2024
- 4Methylphenidate abuse and misuse in patients affected with a psychiatric disorder and a substance use disorder: a systematic reviewPMIDChiappini S, Gramuglia PD, Mosca A et al. · Frontiers in psychiatry · 2024
Chiappini S, Gramuglia PD, Mosca A et al.. Methylphenidate abuse and misuse in patients affected with a psychiatric disorder and a substance use disorder: a systematic review. Frontiers in psychiatry. 2024
- 5Long term methylphenidate exposure and growth in children and adolescents with ADHD. A systematic review and meta-analysisPMIDCarucci S, Balia C, Gagliano A et al. · Neuroscience and biobehavioral reviews · 2021
Carucci S, Balia C, Gagliano A et al.. Long term methylphenidate exposure and growth in children and adolescents with ADHD. A systematic review and meta-analysis. Neuroscience and biobehavioral reviews. 2021
- 6Methylphenidate use in geriatric depression: A systematic reviewPMIDSmith KR, Kahlon CH, Brown JN et al. · International journal of geriatric psychiatry · 2021
Smith KR, Kahlon CH, Brown JN et al.. Methylphenidate use in geriatric depression: A systematic review. International journal of geriatric psychiatry. 2021
- 7Safety of therapeutic methylphenidate in adults: a systematic review of the evidencePMIDGodfrey J · Journal of psychopharmacology (Oxford, England) · 2009
Godfrey J. Safety of therapeutic methylphenidate in adults: a systematic review of the evidence. Journal of psychopharmacology (Oxford, England). 2009
Reviews & position papers
1- 8Methylphenidate for attention-deficit/hyperactivity disorder in adults: a narrative reviewSource linkedPMIDFaraone SV · Psychopharmacol Bull · 2022
Reference material
3- 9MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder (MTA). Arch Gen Psychiatry. 1999.Source linkedPMID
- 10Cortese S et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018.Source linkedPMID
- 11Senior HE et al. Interventions for fatigue management after traumatic brain injury. Cochrane Database Syst Rev. 2026.Source linkedPMID
Common questions.
Quick answers about Methylphenidate, drawn from the data on this page.
What is Methylphenidate?
Prescription central nervous system stimulant (Schedule II controlled substance) approved for attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. One of the most extensively studied medications for ADHD with decades of evidence supporting efficacy. Available in multiple formulations offering various durations of action. Carries risk of abuse, cardiovascular effects, and growth suppression in children. Dosage must be determined by your prescribing physician.
What is Methylphenidate used for?
Commonly cited benefits of Methylphenidate include: Improved attention and focus; Reduced hyperactivity; Decreased impulsivity; Improved academic and occupational performance; Multiple formulation options. NutriStack rates the overall evidence as strong.
What is a typical dose of Methylphenidate?
A typical adult dose of Methylphenidate is 5–60 mg daily for IR; 18–72 mg daily for Concerta ER (as prescribed by your physician). The commonly recommended form is Immediate-release tablet, extended-release tablet/capsule, or transdermal patch. These are general ranges, not personalized advice; confirm the right dose with a clinician.
What are the side effects of Methylphenidate?
Reported side effects include decreased appetite, insomnia, headache, abdominal pain, tachycardia and increased blood pressure, nervousness and anxiety. This is educational information; check with a healthcare professional before use.
How strong is the evidence for Methylphenidate?
NutriStack rates this as Strong, meaning multiple high-quality meta-analyses or systematic reviews converge on the same finding. Full tier criteria are at https://nutristackapp.com/methodology/evidence-tiers.
Use this with your stack
Methylphenidate in NutriStack.
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.